Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the expression of human epidermai growth factor recepetor-2(C-erbB-2) and thyroid transcription factor-1(TTF-1) in endometrial carcinoma and its relationship of prognosis. Methods: To examine the expression of normal endometrium, atypical hyperplasia and endometrial carcinoma by immunohistochemistry, and to discuss both relation to clinical pathological feature and prognosis of endometrial carcinoma. Results: The expression rates of C-erbB-2 in endometrial carcinoma,atypical hyperplasia and normal endometrium were 56.65%, 36.67%, 16.67%(P<0.05), and the expression rates of TTF-1 were 33.75%,53.33%, 70.00%(P<0.05). The positive expression of C-erbB-2 was associated with pathological stage, histological grade, myometrial infiltration and lymphatic metastasis(P<0.05), while not with pathological type(P>0.05). The negative expression of TTF-1 was correlated with pathological stage, histological grade, myometrial infiltration(P<0.05), while not with lymphatic metastasis and pathological type(P>0.05). The expression of C-erbB-2 and TTF-1 in endometrial carcinoma was not associated(P=0.303). The 5-year survival rate was lower in C-erbB-2 positive group than that in negative group(P<0.05). But there was on difference of 5-year survival rate between TTF-1 positive and negative group(P>0.05). Conclusion: The expression of C-erbB-2 of endometrial carcinoma tissues was up-regulatied, while the expression of TTF-1 was down-regulated. Both C-erbB-2 and TTF-1 were involved in the occurrence and development of endometrial carcinoma. The up-regulation of C-erbB-2 was associated with the poor prognosis of endometrial carcinoma. [ABSTRACT FROM AUTHOR]

Objective: To investigate the correlation of serum γ-glutamyl transferase(GGT) level with the influencing factors of coronary heart disease and the severity of patients with vascular disease. Methods: 61 patients diagnosed as coronary heart disease(CHD)from July 2013 to October 2017 in our hospital through coronary angiography were selected as the experimental group, which were divided into stable angina pectoris group(hereinafter referred to as A group, 20 cases), unstable angina(group B, 21 cases) and acute myocardial infarction(group C, 20 cases) according to their clinical symptoms. In the same period, thirty patients without coronary heart disease were selected as the control group. The levels of fasting blood glucose(FBG), total cholesterol(TC), triglyceride(TG), systolic blood pressure(SBP), diastolic blood pressure(DBP) and uric acid in the four groups were measured and compared. The correlation of coronary Gensini score. Finally, the GGT and Gensini scores of four groups of patients were analyzed. Results:(1) The FBG, serum TC,TG, SBP, DBP and uric acid levels in the four groups were significantly different(Group C>Group B>Group A>Control group, P<0.05);(2)The level of GGT was positively correlated with the above risk factors(r=0.236, 0.351, 0.316, 0.239, 0.301, 0.395, P=0.035, 0.000,0.000, 0.0034, 0.001, 0.000);(3)Both GGT and Gensini scores in the four groups were changed according to the trend of Group C>Group B>Group A>Control group(P<0.05);(4) The serum GGT level of patients with coronary heart disease was positively correlated with Gensini score(r=0.681, P=0.000). Conclusion: The serum GGT levels of CHD patients were positively correlated with the serum levels of FBG, TC, TG, SBP, DBP, uric acid levels and the severity of the vascular lesions, it may be used to predict the severity of lesion in CHD patients. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the influence of simvastatin plus low molecular heparin on D-dimer, N-terminal brain natriuretic peptide precursor (NT-pro BNP), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter, serum c-reactive protein (CRP), plasma fibrinogen (FB), serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in patients with chronic heart failure (CHF). Methods: A total of 80 patients with CHF, who were treated in Dalian Center Hospital from April 2010 to July 2014,were selected and randomly divided into treatment group (n=40) and control group (n=40). The two groups were all treated with conventional therapy, based on which, the treatment group was added simvastatin plus low molecular heparin, the course of treatment was two months.The levels of D-dimer, NT-pro BNP, LVEF, left ventricular end-diastolic diameter, CRP, FB, TC and LDL-C in the two groups before and after treatment were compared. Results: Compared with before treatment, the levels of D-dimer, NT-pro BNP, LVEF, left ventricular end-diastolic diameter, CRP, FB, TC and LDL-C in the control group after treatment were not obviously improved, while the above indexes in the treatment group were improved significantly, the differences were statistically significant (P<0.05). Conclusion: Simvastatin plus low molecular heparin can effectively improve the relevant indexe of patients with CHF, which plays an important role in the clinical treatment and is worthy of clinical application. [ABSTRACT FROM AUTHOR]